Pieris Pharmaceuticals Inc banner

Pieris Pharmaceuticals Inc
NASDAQ:PIRS

Watchlist Manager
Pieris Pharmaceuticals Inc Logo
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Watchlist
Price: 12.0296 USD -27.16%
Market Cap: $100.1m

Multiples-Based Value

The Multiples-Based Value of one PIRS stock under the Base Case scenario is 0.8285 USD. Compared to the current market price of 12.0296 USD, Pieris Pharmaceuticals Inc is Overvalued by 93%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PIRS Multiples-Based Value
Base Case
0.8285 USD
Overvaluation 93%
Multiples-Based Value
Price $12.0296
Worst Case
Base Case
Best Case

Multiples Across Competitors

PIRS Competitors Multiples
Pieris Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
100.1m USD 74 -6.3 -4.5 -4.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
376.8B USD 6.3 91.5 15.1 21
US
Exact Sciences Corp
NASDAQ:EXAS
356.2B USD 111.3 -1 738.3 16 147.7 -1 823.3
US
Amgen Inc
NASDAQ:AMGN
188.1B USD 5.1 24.4 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
169.2B USD 5.8 19.9 12.4 15.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.6B USD 9.4 28.5 21.4 22.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 5.7 18.1 13.6 15.5
AU
CSL Ltd
ASX:CSL
67.9B AUD 3.1 34.8 11.5 14.4
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Average P/S: 3 063 018.6
74
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
111.3
12%
9.3
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Average P/E: 36.2
Negative Multiple: -6.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
91.5
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 738.3 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.9
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.5
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
13%
1.4
AU
CSL Ltd
ASX:CSL
34.8
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Average EV/EBITDA: 2 319.4
Negative Multiple: -4.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
12%
1.3
US
Exact Sciences Corp
NASDAQ:EXAS
16 147.7
261%
61.9
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
18%
0.8
AU
CSL Ltd
ASX:CSL
11.5
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Average EV/EBIT: 17.1
Negative Multiple: -4.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 823.3 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.4
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
23%
0.7
AU
CSL Ltd
ASX:CSL
14.4
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett